News & Analysis on Clinical Trial Services & Contract Research And Development
News from PPD, Parallon, ShangPharma and C3i – People on the move
By Natalie Morrison
- Last updated on
Pharmaceutical Product Development (PPD) has named Louis Renzetti VP of strategic laboratory operations.
He joins the firm from Rioche, where he was VP and global head of the RNA therapeutics division.
Lee Babiss, executive VP of global lab services and chief scientific officer, said: “His leadership will be instrumental as we continue implementing innovative new strategies to integrate our laboratory and Phase I services with our Phase II-IV services to provide clients with end-to-end, value-chain capabilities.”
Parallon Business Solutions has appointed Ed Jones as president and CEO of its Health Trust Purchasing Group and Parallon Supply Chain Solutions.
Jones takes the role after serving as interim following former CEO Jim Fitzgerald’s retirement in May.
“We are delighted to have Ed in this critically important position for Parallon. He has a very successful track record of leading strategic supply chain initiatives that have resulted in added-value improvements for our customers and our company,” said Michael O'Boyle, Parallon’s president and CEO.
Yuk Lam Lo has been appointed as the chairman of the independent committee of the company's board of directors for ShangPharma.
The news follows CEO Michael Xin Hui’s proposition to take the CRO (contract research organisation) private.
Business process outsourcing (BPO) firm C3i has drafted in Jonathan Song as business development executive in Asia.
He will support C3i's strategy to expand its clinical and commercial solutions to pharmaceutical, biotechnology and clinical research organisations in the region.
Dave Hanaman, chief sales and marketing officer and co-founder at C3i, said: "His professionalism, customer-focus, and innovative approach to business development will catalyse our growth in Asia and help us to meet our customers' unique needs in this important and rapidly evolving market."
Inclinix-PMG Holdings has appointed John Rubino, Jennifer Byrne and Denise Robinson onto its leadership team.
Joining the firm from Raleigh Medical Group (RMG) Rubino will become medical director for the entire group as well as principal investigator advisory board.
Byrne has been named president and chief operating officer of research at PMG, whilst
Robinson will become president and chief operating officer of Inclinix.
"Together Inclinix and PMG Research bring forth an unrivaled precedent for research site-based experience which will allow for better outcomes for pharmaceutical sponsors, physician investigators, and research participants," Byrne said.
Cadient Group has hired Gabrielle Pastore to lead the healthcare commercial services agency’s newly formed commercial innovation group.
She will take the role of VP of commercial strategy and innovation.
Will Reese, chief innovation officer, said: "She thinks creatively, leads collaboratively, and has extensive global experience building brand value through innovation while producing significant and sustainable business growth."